葡萄糖激酶:从全性葡萄糖感应到疾病变异
Sarah Gersing1, Torben Hansen2, Kresten Lindorff-Larsen1
1Linderstrøm-Lang Centre for Protein Science, Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, Copenhagen, Denmark.
Trends in biochemical sciences
|January 3, 2025
概括
人类葡萄糖激酶 (GCK) 是一种调节胰岛素和糖原合成的葡萄糖传感器. 影响GCK动态的遗传变异与葡萄糖平衡性疾病有关,这促使大规模的变异效应评估.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 代谢调节 代谢调节 代谢调节 代谢调节
背景情况:
- 人类葡萄糖激酶 (GCK) 作为胰腺和肝细胞中的关键葡萄糖传感器.
- GCK 调节胰岛素分泌和糖原合成,这是葡萄糖恒温的关键过程.
- 该酶的独特动态特性,包括低葡萄糖亲和度和西格莫状动态,对于其传感功能至关重要.
研究的目的:
- 审查人类葡萄糖激酶 (GCK) 的结构和功能.
- 探索GCK的动力性质,形状动态及其作为葡萄糖传感器的作用之间的联系.
- 总结一下最近的大规模努力,评估GCK遗传变异对葡萄糖平衡的影响.
主要方法:
- 对人类葡萄糖酶的现有文献的审查.
- 对GCK的动力性质和形状动态的分析.
- 评估GCK遗传变异及其对疾病的影响的研究摘要.
主要成果:
- GCK对葡萄糖的低亲和力和西格体动力学使细胞能够对葡萄糖波动做出反应.
- 酶的动力学与其不寻常的动力行为密切相关.
- 影响GCK功能的遗传变异与三个主要的葡萄糖平衡障碍有关.
结论:
- 人类葡萄糖激酶是重要的葡萄糖传感器,由于其独特的生化特性.
- 了解GCK动态和变异效应对于理解葡萄糖代谢和相关疾病至关重要.
- 目前正在进行的研究重点是对GCK变异的全面评估,以阐明它们的临床意义.
相关概念视频
Glucose Transporters
22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Allosteric Regulation
57.6K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.6K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.1K
Insulin: The Receptor and Signaling Pathways
1.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.1K
Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295


